Skinvisible Reports Mixed Q1 2025 Results Amidst Ongoing Financial Challenges and Stable Revenue

Skinvisible, Inc. (OTCBB: SKVI) recently released its quarterly financial report for the period ending March 31, 2025. While the company is focused on innovative topical delivery systems, it continues to face challenges that are commonplace in the biotech industry.

Positive Aspects:

• Stable Revenue: Total revenues remained relatively stable at $5,000 for both Q1 2025 and Q1 2024.
• Cost Management: Costs of revenue were $0, resulting in consistent gross profit of $5,000 for both periods.
• Improvement in Other Income: Other income decreased to $141,153 in Q1 2025 from a loss of $167,188 in Q1 2024, mainly due to reduced interest expenses.
• Cash Increase: The company saw an increase in cash from $10,336 at the end of 2024 to $13,396 by March 31, 2025.

Negative Aspects:

• Net Loss: The company reported a net loss of $281,005 for Q1 2025, although this is a slight improvement compared to a net loss of $290,372 in Q1 2024.
• Increased Operating Expenses: Operating expenses rose to $144,852 from $128,184 the previous year, largely due to higher selling and administrative costs.
• Working Capital Deficit: The working capital deficit worsened to $4,218,598 from $3,615,238 as of December 31, 2024.
• Cumulative Losses: The company has incurred total cumulative losses of $40,227,147 since inception, raising concerns about its ability to continue as a going concern.

Key Statistics:

• Share Performance: Basic loss per share decreased to $(0.05) from $(0.06) year-over-year.
• Current Assets: Total current assets decreased to $38,305 from $42,028 as of December 31, 2024.
• Total Assets: Skinvisible's total assets reduced to $149,554 compared to $158,217 at year-end 2024.
• Total Liabilities: Total liabilities increased slightly to $9,629,306 from $9,381,744.
• Shares Outstanding: The total number of common shares outstanding increased to 5,403,843 from 5,316,843.

Outlook: While Skinvisible, Inc. has opportunities in licensing its patented products, its significant financial losses and working capital challenges present ongoing concerns. The company must secure additional funding and improve operational efficiencies to achieve sustainable growth.